BMRN logo

BioMarin Pharmaceutical Inc.

BMRN
Healthcare|Biotechnology|US
$56.03
-0.09 (-0.16%)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80
Next Earnings Report
Feb 22, 2027
EPS est. $0.82 · Revenue est. $1.09B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (21)

Mar 2027
Est. completion
P2Noonan Syndrome
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Apr 2027
Est. completion
P1P2Duchenne Muscular Dystrophy
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
Jul 2027
Est. completion
P1Claudication, Intermittent
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
Sep 2027
Est. completion
P4Phenylketonuria
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
Dec 2027
Est. completion
P2Achondroplasia
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
Dec 2027
Est. completion
P2Achondroplasia
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
Dec 2027
Est. completion
P1P2Phenylketonuria (PKU)
AAV Gene Therapy Study for Subjects with PKU
Feb 2028
Est. completion
Achondroplasia
VIrtual STudy in Achondroplasia for the US (VISTA)
Jun 2028
Est. completion
P2Hypochondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Nov 2028
Est. completion
P1P2Hereditary Angioedema
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
Dec 2028
Est. completion
Phenylketonurias
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Jun 2029
Est. completion
P2P3Achondroplasia
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Aug 2030
Est. completion
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Cerliponase Alfa Observational Study in the US
Dec 2030
Est. completion
Achondroplasia
Achondroplasia Natural History Multicenter Clinical Study
Jun 2031
Est. completion
P3Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Oct 2032
Est. completion
Phenylketonuria, Maternal
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
Nov 2033
Est. completion
Phenylketonuria (PKU)
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
Nov 2033
Est. completion
Phenylketonuria (PKU)
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
May 2038
Est. completion
P2Achondroplasia
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
Dec 2040
Est. completion
Idiopathic Short Stature
A Study to Assess Growth in Children With Idiopathic Short Stature

Awaiting Results (4)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P1
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017
Aug 2026
P3
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059
Apr 2025
P3
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907
Jan 2025
P3
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837

SEC Filings (69)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 2, 20268-KMaterial eventDocumentIndex
Oct 6, 20268-KMaterial eventDocumentIndex
Sep 30, 20268-KMaterial eventDocumentIndex
Sep 15, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Sep 1, 20268-KMaterial eventDocumentIndex
Aug 31, 20268-KMaterial eventDocumentIndex
Aug 18, 20268-KMaterial eventDocumentIndex
Aug 6, 2026S-8Employee stock planDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 13, 20268-K/AMaterial eventDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 27, 20268-KMaterial eventDocumentIndex
Apr 23, 20268-KMaterial eventDocumentIndex
Apr 21, 2026ARSAnnual report to holdersDocumentIndex
Apr 21, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 21, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 16, 20268-KMaterial eventDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 23, 20268-KMaterial eventDocumentIndex
Feb 12, 20268-KMaterial eventDocumentIndex
Jan 29, 20268-KMaterial eventDocumentIndex
Jan 26, 20268-KMaterial eventDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 22, 20258-KMaterial eventDocumentIndex
Dec 19, 20258-KMaterial eventDocumentIndex
Dec 17, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 28, 202510-QQuarterly reportDocumentIndex
Oct 27, 20258-KMaterial eventDocumentIndex
Oct 7, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex